Paper 84 - PLANNED ANALYSIS OF THE PIVOTAL IGNYTE-ESO TRIAL OF LETE-CEL IN PATIENTS WITH SYNOVIAL SARCOMA OR MYXOID/ROUND CELL LIPOSARCOMA.

Author(s)

• SD

  Sandra P. D'Angelo, MD

  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York, United States

  Slides

Co-Author(s)

• AF

  Andrew J.S. Furness, MD, PhD

  The Royal Marsden NHS Foundation Trust
  London, England, United Kingdom
• FT

  Fiona Thistlethwaite, MB, BChir, PhD, MRCP

  The Christie NHS Foundation Trust and University of Manchester
  Manchester, England, United Kingdom
• MB

  Melissa A. Burgess, MD

  University of Pittsburgh Medical Center
  Pittsburgh, Pennsylvania, United States
• RR

  Richard F. Riedel, MD

  Duke Cancer Institute
  Durham, North Carolina, United States
• JH

  John Haanen, MD

  Netherlands Cancer Institute
  Amsterdam, Noord-Holland, Netherlands
• JN

  Jonathan Noujaim, MD

  Hôpital Maisonneuve-Rosemont
  Montreal, Quebec, Canada
• 

  Anna W. Chalmers, MD (she/her/hers)

  Assistant Professor
  Huntsman Cancer Institute, University of Utah
  Salt Lake City, Utah, United States
• AL

  Antonio López Pousa, MD

  Hospital Santa Creu Y Sant Pau
  Barcelona, Catalonia, Spain
• RC

  Rashmi Chugh, MD

  Clinical Professor
  University of Michigan Rogel Comprehensive Cancer Center
  Ann Arbor, Michigan, United States
• 

  Lara E. Davis, MD (she/her/hers)

  Associate Professor
  Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University
  Portland, Oregon, United States
• EF

  Edouard Forcade, MD, PhD

  Centre Hospitalier Universitaire de Bordeaux – Hôpital Haut-Lévêque
  Bordeaux, Aquitaine, France
• MA

  Mark Agulnik, MD

  City of Hope
  Duarte, California, United States
• AP

  Andrew Poklepovic, MD

  School of Medicine, Virginia Commonwealth University
  Richmond, Virginia, United States
• MS

  Maria Pilar Sancho Marquez, MD

  Hospital Universitario Virgen del Rocio
  Seville, Andalucia, Spain
• AS

  Armando Santoro, MD

  Cancer Center at Humanitas Research Hospital
  Milan, Lombardia, Italy
• SS

  Silvia Stacchiotti, MD

  Medical Oncologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• SS

  Sandra J. Strauss, FRCP

  UCL Cancer Institute, University College London NHS Foundation Trust
  London, England, United Kingdom
• 

  Brian A. Van Tine, MD, PhD

  Professor of Medicine
  Washington University in St. Louis
  Saint Louis, Missouri, United States
• KG

  Kristen N. Ganjoo, MD

  Stanford Comprehensive Cancer Center
  Palo Alto, California, United States
• DL

  David A. Liebner, MD

  The Ohio State University Comprehensive Cancer Center
  Columbus, Ohio, United States
• KK

  Kavya Kazipeta, MSc

  Adaptimmune
  Philadelphia, Pennsylvania, United States
• DW

  Dennis Williams, PharmD

  Adaptimmune
  Philadelphia, Pennsylvania, United States
• MW

  Mary A. Woessner, PhD

  GlaxoSmithKline
  Durham, North Carolina, United States
• TF

  Thomas Faitg, PhD

  GlaxoSmithKline
  Philadelphia, Pennsylvania, United States
• BI

  Beth Ireland, MSc

  Adaptimmune
  Abingdon, England, United Kingdom
• 

  Michael J. Nathenson, MD (he/him/his)

  Senior Medical Director
  Adaptimmune
  Cambridge, Massachusetts, United States
• EN

  Elliot Norry, MD

  Adaptimmune
  Philadelphia, Pennsylvania, United States
• AA

  Albiruni Abdul Razak, MB BCh, BAO, LRCP & SI

  Toronto Sarcoma Program, Princess Margaret Cancer Center
  Toronto, Ontario, Canada